Literature DB >> 6087960

Kinetics and mechanism of the bactericidal action of human neutrophils against Escherichia coli.

M N Hamers, A A Bot, R S Weening, H J Sips, D Roos.   

Abstract

A mutant strain of Escherichia coli (E. coli ML-35) was used to follow the kinetics of phagocytosis, perforation of the bacterial cell envelope, and inactivation of bacterial proteins by human neutrophils. This particular E. coli mutant strain has no lactose permease, but constitutively forms the cytoplasmic enzyme beta-galactosidase. This implies that the artificial substrate ortho-nitrophenyl-beta-D-galactopyranoside cannot reach the beta-galactosidase unless the bacterial cell envelope has been perforated. Thus, the integrity of the E. coli envelope can be measured simply by the activity of beta-galactosidase with this substrate. Indeed, ingestion of E. coli ML-35 by human neutrophils was followed by perforation of the bacteria (increase in beta-galactosidase activity). Subsequently, the beta-galactosidase activity decreased due to inactivation of the enzyme. With a simple mathematical model and a curve-fitting computer program, we have determined the first-order rate constants for phagocytosis, perforation, and beta-galactosidase inactivation. With 32 normal donors, we found an interdonor variation in these rate constants of 20% to 30% (SD) and an assay variance of 5%. The perforation process closely correlated with the loss of colony-forming capacity of the bacteria. This new assay measures phagocytosis and killing in a fast, simple, and accurate way; it is not hindered by extracellular bacteria. Moreover, this method also measures the postkilling event of inactivation of a bacterial protein, which permits a better detection of neutrophils deficient in this function. The assay can also be used for screening neutrophil functions without the use of a computer program. A simple calculation suffices to detect neutrophil abnormalities. Neutrophils from patients with chronic granulomatous disease (CGD) showed an impaired rate of perforation and thus also of inactivation. Neutrophils from myeloperoxidase-deficient patients or from a patient with the Chediak-Higashi syndrome only showed a retarded inactivation of beta-galactosidase, but normal ingestion and perforation. The role of myeloperoxidase in the killing process is discussed. Although myeloperoxidase does not seem to be a prerequisite for perforation, it probably plays a role in bacterial destruction by normal cells, because the inactivation of bacterial proteins seems strictly myeloperoxidase dependent.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6087960

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  Action of hypochlorous acid on the antioxidant protective enzymes superoxide dismutase, catalase and glutathione peroxidase.

Authors:  O I Aruoma; B Halliwell
Journal:  Biochem J       Date:  1987-12-15       Impact factor: 3.857

2.  Redundant contribution of myeloperoxidase-dependent systems to neutrophil-mediated killing of Escherichia coli.

Authors:  H Rosen; B R Michel
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

3.  The impact of platelet-activating factor (PAF)-like mediators on the functional activity of neutrophils: anti-inflammatory effects of human PAF-acetylhydrolase.

Authors:  T W Kuijpers; J M van den Berg; A T Tool; D Roos
Journal:  Clin Exp Immunol       Date:  2001-03       Impact factor: 4.330

4.  Interaction of human defensins with Escherichia coli. Mechanism of bactericidal activity.

Authors:  R I Lehrer; A Barton; K A Daher; S S Harwig; T Ganz; M E Selsted
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

5.  Bactericidal action of eosinophils from normal human blood.

Authors:  M Yazdanbakhsh; C M Eckmann; A A Bot; D Roos
Journal:  Infect Immun       Date:  1986-07       Impact factor: 3.441

6.  Identification of a homozygous deletion in the AP3B1 gene causing Hermansky-Pudlak syndrome, type 2.

Authors:  Johannes Jung; Georg Bohn; Anna Allroth; Kaan Boztug; Gudrun Brandes; Inga Sandrock; Alejandro A Schäffer; Chozhavendan Rathinam; Inga Köllner; Carmela Beger; Reinhard Schilke; Karl Welte; Bodo Grimbacher; Christoph Klein
Journal:  Blood       Date:  2006-03-14       Impact factor: 22.113

7.  Bistability and bacterial infections.

Authors:  Roy Malka; Eliezer Shochat; Vered Rom-Kedar
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

8.  Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapy.

Authors:  Christian Brendel; Walther Hänseler; Vital Wohlgensinger; Matteo Bianchi; Serap Tokmak; Linping Chen-Wichmann; Elena Kuzmenko; Nikola Cesarovic; Flora Nicholls; Janine Reichenbach; Reinhard Seger; Manuel Grez; Ulrich Siler
Journal:  Hum Gene Ther Methods       Date:  2013-05-02       Impact factor: 2.396

9.  Degradation of biomaterials by phagocyte-derived oxidants.

Authors:  K Sutherland; J R Mahoney; A J Coury; J W Eaton
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

10.  Enhanced resistance against Escherichia coli infection by subcutaneous administration of the hot-water extract of Chlorella vulgaris in cyclophosphamide-treated mice.

Authors:  F Konishi; K Tanaka; S Kumamoto; T Hasegawa; M Okuda; I Yano; Y Yoshikai; K Nomoto
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.